Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

121
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
121
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

245
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
245
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

394
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
394
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

491
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
491
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

106
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
106
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

242
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
242

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinicopathologic characterization of renal tumors with Folliculin (FLCN) biallelic inactivation.

Virchows Archiv : an international journal of pathology·2026
Same author

Diagnostic Utility of Immunofixation and Free Light Chain Assay in AL Amyloidosis: A Systematic Review and Meta-analysis.

Blood advances·2026
Same author

Is There a Role for Pentoxifylline in Diabetic Kidney Disease? A Mini Review.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

LUMBER: A feasible MRI-based 3D printed mould platform for ex vivo sampling of prostate cancer.

BJUI compass·2026
Same author

American Society of Hematology (ASH) 2026 Guidelines on Diagnosis of Light Chain Amyloidosis.

Blood advances·2026
Same author

The role of cardiac imaging for diagnosis of cardiac amyloidosis: a systematic review and meta-analysis of test accuracy.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2026

Related Experiment Video

Updated: Nov 9, 2025

Intravenous Microinjections of Zebrafish Larvae to Study Acute Kidney Injury
15:55

Intravenous Microinjections of Zebrafish Larvae to Study Acute Kidney Injury

Published on: August 4, 2010

22.9K

Acute Kidney Injury Associated With Semaglutide.

David J Leehey1,2, Mohamed A Rahman3, Ewa Borys1

  • 1Loyola University Medical Center, Maywood, IL.

Kidney Medicine
|April 14, 2021
PubMed
Summary

Glucagon-like peptide 1 (GLP-1) receptor agonists like semaglutide may worsen kidney function in patients with existing chronic kidney disease. Caution is advised, especially for those with moderate to severe disease, and monitoring is recommended.

Keywords:
Glucagon-like peptide-1 (GLP-1) receptor agonistsacute kidney injury (AKI)chronic kidney disease (CKD)diabetic kidney diseasediabetic nephropathysemaglutide

More Related Videos

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
09:02

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

4.7K
Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury
07:58

Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury

Published on: July 17, 2016

9.1K

Related Experiment Videos

Last Updated: Nov 9, 2025

Intravenous Microinjections of Zebrafish Larvae to Study Acute Kidney Injury
15:55

Intravenous Microinjections of Zebrafish Larvae to Study Acute Kidney Injury

Published on: August 4, 2010

22.9K
A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
09:02

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

4.7K
Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury
07:58

Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury

Published on: July 17, 2016

9.1K

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Glucagon-like peptide 1 (GLP-1) receptor agonists are used for type 2 diabetes.
  • Previous reports suggest potential acute kidney injury with GLP-1 receptor agonists (exenatide, liraglutide).

Observation:

  • Two patients with diabetic kidney disease and chronic kidney disease experienced rapid kidney function decline and increased proteinuria after starting semaglutide.
  • One patient's biopsy revealed advanced glomerulosclerosis, interstitial inflammation, and acute tubular injury.

Findings:

  • Semaglutide use was associated with acute kidney injury in patients with pre-existing chronic kidney disease.
  • The long-term outcomes of such acute kidney injury events remain unknown.

Implications:

  • Caution is recommended when prescribing GLP-1 receptor agonists to patients with moderate to severe chronic kidney disease.
  • Patients experiencing gastrointestinal symptoms alongside adverse kidney events should be monitored, with potential medication discontinuation.
  • Further research is needed to understand the long-term renal outcomes associated with GLP-1 receptor agonist use in vulnerable populations.